Essential Thrombocythemia - Pipeline Review, H2 2016

Date: October 29, 2016
Pages: 82
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EB1FF66DDBFEN
Leaflet:

Download PDF Leaflet

Essential Thrombocythemia - Pipeline Review, H2 2016
Essential Thrombocythemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Essential Thrombocythemia - Pipeline Review, H2 2016, provides an overview of the Essential Thrombocythemia (Oncology) pipeline landscape.

Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essential thrombocythemia, there is mainly an overproduction of platelet forming cells (megakaryocytes) in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech and transient ischemic attacks.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Essential Thrombocythemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Essential Thrombocythemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Essential Thrombocythemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 3, 6 and 1 respectively for Essential Thrombocythemia.

Essential Thrombocythemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Essential Thrombocythemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Essential Thrombocythemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Essential Thrombocythemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Essential Thrombocythemia (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Essential Thrombocythemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Essential Thrombocythemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Essential Thrombocythemia Overview
Therapeutics Development
Pipeline Products for Essential Thrombocythemia - Overview
Essential Thrombocythemia - Therapeutics under Development by Companies
Essential Thrombocythemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Essential Thrombocythemia - Products under Development by Companies
Essential Thrombocythemia - Companies Involved in Therapeutics Development
Aop Orphan Pharmaceuticals AG
F. Hoffmann-La Roche Ltd.
Galena Biopharma, Inc.
Gilead Sciences, Inc.
Incyte Corporation
Italfarmaco S.p.A.
MEI Pharma, Inc.
Novartis AG
PharmaEssentia Corporation
Essential Thrombocythemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
anagrelide hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anagrelide hydrochloride PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
momelotinib dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pracinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropeginterferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sonidegib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vismodegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Essential Thrombocythemia - Dormant Projects
Essential Thrombocythemia - Discontinued Products
Essential Thrombocythemia - Product Development Milestones
Featured News & Press Releases
Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
Jun 13, 2016: Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance
May 31, 2011: YM BioSciences Announces Orphan Drug Designation For JAK1/JAK2 Inhibitor CYT387 In Europe
Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting
May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 82

LIST OF TABLES

Number of Products under Development for Essential Thrombocythemia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Products under Development by Companies, H2 2016
Essential Thrombocythemia - Pipeline by Aop Orphan Pharmaceuticals AG, H2 2016
Essential Thrombocythemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Essential Thrombocythemia - Pipeline by Galena Biopharma, Inc., H2 2016
Essential Thrombocythemia - Pipeline by Gilead Sciences, Inc., H2 2016
Essential Thrombocythemia - Pipeline by Incyte Corporation, H2 2016
Essential Thrombocythemia - Pipeline by Italfarmaco S.p.A., H2 2016
Essential Thrombocythemia - Pipeline by MEI Pharma, Inc., H2 2016
Essential Thrombocythemia - Pipeline by Novartis AG, H2 2016
Essential Thrombocythemia - Pipeline by PharmaEssentia Corporation, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Essential Thrombocythemia - Dormant Projects, H2 2016
Essential Thrombocythemia - Discontinued Products, H2 2016 74

LIST OF FIGURES

Number of Products under Development for Essential Thrombocythemia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Essential Thrombocythemia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: